

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 December 2010 (16.12.2010)

PCT

(10) International Publication Number
WO 2010/144265 A2

(51) International Patent Classification:
A61K 9/08 (2006.01)

(21) International Application Number:
PCT/US2010/036365

(22) International Filing Date:
27 May 2010 (27.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/186,595 12 June 2009 (12.06.2009) US

(71) Applicant (for all designated States except US):
HELSINN THERAPEUTICS (U.S.), INC. [US/US];
1160 U.S. Highway 22, Suite 104, Bridgewater, NJ 08807
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RUBIO, Silvina, Garcia** [UY/US]; 7 Bellflower Court, Princeton, NJ 08540 (US). **BEIDLER, Daniel** [US/US]; 14057 Painted Desert Road, Poway, CA 92064 (US). **WEIBEL, Helle** [DK/DK]; Rideknaegtsvej 11, DK-3400 Hillerød (DK). **BRAGLIA, Riccardo** [CH/CH]; Via S. Salvatore 9, CH-6913 Lugano-carabbia (CH).

(74) Agent: **SULLIVAN, Clark, G.**; Arnall Golden Gregory LLP, 171 17th Street, Nw, Suite 2100, Atlanta, GA 30363-1031 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: IPAMORELIN DIACETATE INJECTION AND INFUSION SOLUTIONS

(57) Abstract: Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin; b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7; c) optionally from 0.1 to 30% of one or more formulation aids; and d) water q.s. to 100%; all percentages based on the total weight of the solution.



WO 2010/144265 A2